Press Coverage is a Service that we offer to Biotech and Medicine, Scientific and Business Conference Organizers.
Click on these Links
-
Part One: The Process of Real Time Coverage using Social Media
-
Part Two: List of BioTech Conferences 2013 to Present
-
Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics
YEAR |
Tweed Collections# of Views |
$ |
Grand Total$Potential Revenues from DOWNLOADSe-Proceedings and Tweet Collections at $100 per item |
Grand Total Views2013 – 2019 |
Total Aviva Lev-Ari & Stephen J Williams |
1,090 |
109,000 |
1,368,500 |
13,685 |
YEAR |
# Events Covered generating e-Proceeding (some events covered by iPhone Tweeting Pictures and Comments, only) Event counted as 1 even if it generated multiple article entires |
e-Proceedings # of Views |
$ |
Tweets Collections (TC) generated# of Items |
Total Aviva Lev-Ari & Stephen J Williams |
60 |
12,595 |
1,259,500 |
36 |
List of Conferences Covered in Real Time by
Aviva Lev-Ari, PhD, RN and by Stephen J Williams, PhD on Press Pass, 2013 – Present
YEAR | 60 | CONFERENCES | COVERED BY | |
2019 | 13 | MassBio | AVIVA | |
WMIF-AI-Partners | AVIVA | |||
US-India BioPharma | AVIVA | |||
BioIT | AVIVA | |||
Koch@MIT 1/19 & 6/14, | AVIVA | |||
Petrie-Flom, HLS | AVIVA | |||
BU- Data Science, 8/22 | AVIVA | |||
HMS, 10/3 | AVIVA | |||
Charles River Labs, 9/23-24, | AVIVA | |||
PMC, 11/13-14 | AVIVA | |||
NE Venture | AVIVA | |||
#BIO-2019 | WILLIAMS | |||
2018 | 11 | MassBio – AI, ML&CL | AVIVA | |
MassBio – Devices & Drugs | AVIVA | |||
WMIF – AI Partners | AVIVA | |||
US-India BioPharm | AVIVA | |||
BioIT | AVIVA | |||
Bio2018 | AVIVA | |||
Koch&^MIT | AVIVA | |||
CHI-Discovery OnTarget | AVIVA | |||
PMC-HMS | AVIVA | |||
MassBio | AVIVA | |||
WMIF-IO CHI | AVIVA | |||
Symposium on Mediterranean Diet | WILLIAMS | |||
MedCity | WILLIAMS | |||
2017 | 12 | OncoVirus IO | AVIVA | |
WarrenLecture-HMS | AVIVA | |||
HubWeek | AVIVA | |||
EmTech@MIT Media Lab | AVIVA | |||
PMC-HMS | AVIVA | |||
MassBio | AVIVA | |||
US-India Pharma | AVIVA | |||
WMIF-Cardiovascular Partners | AVIVA | |||
2016 | 8 | CHI-OncoVirus IO | AVIVA | |
CHI – Discovery OnTarget | AVIVA | |||
EmTech@MIT | AVIVA | |||
PMC-HMS | AVIVA | |||
MassBio | AVIVA | |||
BioIT | AVIVA | |||
US-India Pharma | AVIVA | |||
AACR | WILLIAMS | |||
CHI – NGS | WILLIAMS | |||
CHI – CRISPR | AVIVA | |||
WMIF-CANCER Partners | AVIVA | |||
Biotech Week Boston | AVIVA | |||
5 | EmTech@MIT | AVIVA | ||
2015 | ||||
PMC-HMS | AVIVA | |||
SacksAssoc-NY | AVIVA | |||
MassBio | AVIVA | |||
BioIT | AVIVA | |||
AVIVA | ||||
PMWC – Silicon Valley | AVIVA | |||
Life Sciences Collaborative 2015 Meeting
3D Printing AACR
|
WILLIAMS | |||
WILLIAMS | ||||
WILLIAMS | ||||
7 | Koch@MIT | AVIVA | ||
2014 | ||||
SacksAssoc – Basel | AVIVA | |||
Gabbay Award -Brandeis | AVIVA | |||
PMC-HMS | AVIVA | |||
PCCI | WILLIAMS | |||
1st Pitch Life Sciences | WILLIAMS | |||
2013 | 1 | BioIT | AVIVA |
Channels for e-Marketing of Biotech Conferences
-
Our Journal http://pharmaceuticalintelligence.com
On 3/3/2020
- 1,723,362 e-Readers
- 5,742 Articles
- 694 Research Categories – Journal Ontology
- 10,154Tags
- 7,379 Global scientists comments
- Aviva’s +7,164 BIOTECH Followers on LinkedIn
http://www.linkedin.com/in/avivalevari
- Aviva is a Member of +60 LinkedIn Groups in Biotech related fields
https://www.linkedin.com/groups/my-groups
- LPBI Group’s FaceBook Page
http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence
- We co-Market and Co-Promote Events
- LPBI Group’s Twitter Account
- LinkedIn (LI) Group Launcher and Manager of Three LI Groups
Cardiovascular Biotech & Pharma UK & US Networking Group
918 members (1/2019)Leaders in Pharmaceutical Business Intelligence
342 members (1/2019)Innovation in Israel
197 members (1/2019)
- LPBI Group’s Company’s Page on LinkedIn
OTHER CONFERENCES in 2020
Mar 22nd 2020 | Paris, France Mar 23rd 2020 | Paris, France Mar 23rd – 25th 2020 | Paris, France Pharma-Biotech Product & Company Valuation Apr 20th 2020 | Basel, Switzerland Swiss Biotech Day (HelloPartnering Event*) Apr 21st 2020 | Basel, Switzerland BioFuture (HelloPartnering Event*) Apr 27th – 29th 2020 | New York, USA BioTrinity 2020 (HelloPartnering Event*) Apr 28th – 29th 2020 | London, United Kingdom Biotech Product and Company Valuation POSTPONED May 5th 2020 | Shanghai, China ChinaBio™ Partnering Forum POSTPONED May 6th – 7th 2020 | Suzhou, China May 18th – 19th 2020 | Boston, USA Product and Company Valuation Course Jun 7th 2020 | San Diego, USA The Redefining Early Stage Investments (RESI) Jun 8th 2020 | San Diego, USA Jun 8th – 11th 2020 | San Diego, USA Jun 30th – Jul 1st 2020 | Singapore BIOHK2020 (HelloPartnering Event*) Aug 19th – 22nd 2020 | Hong Kong |
This page has the following sub pages.
I actually consider this amazing blog , âSAME SCIENTIFIC IMPACT: Scientific Publishing –
Open Journals vs. Subscription-based « Pharmaceutical Intelligenceâ, very compelling plus the blog post ended up being a good read.
Many thanks,Annette
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
[…] Press Coverage […]